Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

10.45 -0.06 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 348,054
Open 10.60
Bid (Size) 10.38 (1)
Ask (Size) 11.31 (1)
Prev. Close 10.51
Today's Range 10.38 - 10.60
52wk Range 7.070 - 15.43
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
From Evolus
Via Business Wire
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
From Evolus
Via Business Wire

Performance

YTD
+4.60%
+4.60%
1 Month
-17.26%
-17.26%
3 Month
-24.55%
-24.55%
6 Month
+4.19%
+4.19%
1 Year
+41.60%
+41.60%

More News

Read More
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus: Chiseling Away At The Aesthetic Market
Via Talk Markets
Recap: Evolus Q4 Earnings
Via Benzinga
Earnings Outlook For Evolus
Via Benzinga
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
From Evolus
Via Business Wire
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
From Evolus, Inc.
Via Business Wire
EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Evolus Reports First Quarter 2024 Results and Provides Business Update
From Evolus
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Evolus to Report First Quarter Financial Results on May 7, 2024
From Evolus
Via Business Wire
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
From Evolus
Via Business Wire
Evolus Announces Results from European Head-to-Head Filler Trial
From Evolus
Via Business Wire
Earnings Scheduled For March 7, 2024
Via Benzinga
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
From Evolus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.